新华制药：子公司获熊去氧胆酸胶囊药品注册证书

Group 1 - The company announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Ursodeoxycholic Acid Capsules from the National Medical Products Administration [1] - The drug is indicated for the treatment of cholesterol gallstones, cholestatic liver disease, and bile reflux gastritis [1] - The estimated sales revenue for Ursodeoxycholic Acid in Chinese public medical institutions is approximately RMB 2.155 billion in 2024 [1]